Subretinal Macugen® for Neovascular Age-Related Macular Degeneration

Inclusion Criteria:

• Adults aged 50 years and older with neovascular AMD proven by FA

• Patients who at baseline

• Have a BCVA letter score in the study eye between 20/40 to 20/320 using an ETDRS chartmeasured at 4 meters or Snellen equivalent

• Have a CNV lesion of any type in the study eye with the following characteristics asdetermined by fluorescein angiography:

• Evidence that CNV extends under the geometric center of the foveal avascular zone.

• Previous state-of-the-art therapy for the disease is deemed ineffective with followingcharacteristics are given:

• Loss of visual acuity (2 or more Snellen lines) in the previous 3 months defined aseither OR

• ≥10% increase in the lesion diameter as assessed by fluorescein angiography in theprevious 3 months

• Ability of subject to understand character and individual consequences of clinicaltrial.

• Signed and dated informed consent of the subject must be available before start of anyspecific trial procedures.

• Women with childbearing potential practicing a medically accepted contraception (negative pregnancy test result, serum or urine at trial entry).

Exclusion Criteria:

• Subjects presenting with any of the following criteria will not be included in thetrial:

• Have a relevant ocular disease which may be associated with increased intraocularVEGF levels (namely uveitis, neovascular glaucoma, diabetic retinopathy, diabeticmaculopathy, ocular ischemic syndrome, retinal vessel occlusion)

• Had previous vitrectomy surgery for whatsoever reason

• Are not pseudophakic

• Have a >50% area of scarring of the whole CNV lesion size as seen in FA

• Arterial hypertension refractory to medical treatment

• Pregnancy and lactation.

• History of hypersensitivity to the investigational medicinal product or to anydrug with similar chemical structure or to any excipient present in thepharmaceutical form of the investigational medicinal product.

• Participation in other clinical trials during the present clinical trial orwithin the last 3 months.

• Medical or psychological condition that would not permit completion of the trialor signing of informed consent.

• Suspected or present ocular or periocular infection